Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias

By sjmartinez • May 7, 2025

Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias. Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-2764. Epub ahead of print. PMID: 40327322.

Tags: Hematology/Oncology, Publications

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Jiang H, Limsuwannarot S, Kulhanek KR, Pal A, Labiad O, Rysavy LW, Wong A, Su L, Cavender S, Soro J, Testa S, Ogana H, Waghray[...]

Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy

Hammer PM, Enamandram S, Ikeda DM, Lam MM, Wapnir IL, Chamberlain ED, Shaheen S, Caswell-Jin JL, Itakura H, Bean GR. Mammary small cell neuroendocrine carcinomas[...]

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM,[...]